Key Factor Supporting Global Claudin 18.2 Targeted Therapy Market Development in 2025: Rising Gastrointestinal Cancer Incidence Driving The Market Growth Due To Increasing Prevalence And Unhealthy Diets

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Claudin 18.2 Targeted Therapy Market Size By 2025?
The market for claudin 18.2 targeted therapy has seen massive growth recently. The market size is predicted to increase from $1.29 billion in 2024 to $1.60 billion in 2025, marking a compound annual growth rate (CAGR) of 23.9%. Reasons for this rapid growth in the previous period include heightened research and development operations, more support from government and institutional bodies, a surge in pancreatic cancer cases, increased healthcare spending on oncology, and wider global availability of targeted therapies.

How Big Is the Claudin 18.2 Targeted Therapy Market Size Expected to Grow by 2029?
Over the coming years, the market size for claudin 18.2 targeted therapy is predicted to undergo a significant surge, swelling to $3.73 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 23.6%. Several factors will fuel this growth during the forecast period, including the approval of more cldn18.2-based therapies, increasing instances of gastric and gastroesophageal junction (gej) cancers, a burgeoning pipeline of cldn18.2-specific therapies, heightened interest from pharmaceutical organizations, and an increasing trend of personalized medicine. The forecast period will also witness certain key trends such as advancements in the creation of monoclonal antibodies, fresh breakthroughs in bispecific antibody therapies, advances in antibody-drug conjugates, investments in the discovery and validation of biomarkers, and ongoing research and development in combination therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report

Which Key Market Drivers Powering Claudin 18.2 Targeted Therapy Market Expansion and Growth?
The escalation in cases of gastrointestinal cancers is anticipated to drive the expansion of the claudin 18.2 targeted therapy market. Gastrointestinal (GI) cancers include malignant tumours appearing anywhere within the digestive tract, ranging from the esophagus to the rectu*m. The surge in such cancers can be attributed primarily to poor dietary habits marked by high consumption of processed foods and a lack of fiber, which fosters gut inflammation and elevates the risk of cancer. Claudin 18.2 targeted therapy is effective in treating gastrointestinal cancers by sole focus on the Claudin 18.2 protein, which is ere*xpressed on cancer cells. This enables medications or antibodies to annihilate cancer cells while leaving healthy tissue unharmed, thereby enhancing the effectiveness of treatment. For instance, the National Library of Medicine, a US federal government entity, highlighted in July 2025 that in the year 2022, gastrointestinal (GI) cancers made up 4,783,391 new instances and caused 3,235,719 fatalities, amounting to 23.9% of all fresh cancer instances and 33.2% of all cancer-associated deaths across the globe. Therefore, the escalating prevalence of gastrointestinal cancers is facilitating the expansion of the Claudin 18.2 targeted therapy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Claudin 18.2 Targeted Therapy Market?
Major players in the claudin 18.2 targeted therapy market are concentrating on creating novel solutions, for example, monoclonal antibodies, that precisely target claudin 18.2-expressing tumors to improve the outcomes of treatments. A monoclonal antibody is a lab-produced protein that's designed to attach to just one particular target, like a protein on a cancer cell, supporting the immune system's ability to identify and attack these cells. In March 2024, for example, Astellas Pharma Inc., a Japanese pharmaceutical company, got approval from the Ministry of Health, Labour and Welfare of Japan for VYLOY (zolbetuximab) to treat patients with CLDN18.2-positive cancer. This particular therapy for advanced gastric and gastroesophageal junction cancer selectively connects to the CLDN18.2 protein on tumor cells, triggering the immune system to destroy the cancer cells. Clinical trials have revealed that this therapy significantly boosts progression-free and overall survival when used alongside chemotherapy, compared to chemotherapy on its own. This breakthrough therapeutic method offers a practical new choice for patients with HER2-negative, CLDN18.2-positive tumors, addressing an underserved need in severe gastric cancer.

What Are the Emerging Segments in the Claudin 18.2 Targeted Therapy Market?
The claudin 18.2 targeted therapy market covered in this report is segmented as

1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users

Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28169&type=smp

Who Are the Global Leaders in the Claudin 18.2 Targeted Therapy Market?
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

Which are the Top Profitable Regional Markets for the Claudin 18.2 Targeted Therapy Industry?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in claudin 18.2 targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28169

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.